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Abstract. 
 
Studies in cell culture systems have indicated 
that oncogenic forms of Ras can affect apoptosis. Acti-
vating mutations of Ras occur in 
 
z
 
30% of all human 
tumors and 50% of colorectal carcinomas. Since these 
mutations appear at early or intermediate stages in 
multistep journeys to neoplasia, an effect on apoptosis 
may help determine whether initiated cells progress to-
wards a more neoplastic state. We have tested the ef-
fects of K-ras
 
Val12
 
 on apoptosis in transgenic mice. A 
lineage-specific promoter was used to direct expression 
of human K-ras
 
Val12
 
, with or without wild-type (wt) or 
mutant SV-40 T antigens (TAg), in postmitotic villus 
enterocytes, the principal cell type of the small intesti-
nal epithelium. Enterocytes can be induced to reenter 
the cell cycle by TAg
 
Wt
 
. Reentry is dependent upon the 
ability of TAg to bind pRB and is associated with a p53-
independent apoptosis. Analyses of K-ras
 
Val12
 
 
 
3
 
 TAg
 
Wt
 
 
bi-transgenic animals indicated that K-ras
 
Val12
 
 can en-
hance this apoptosis threefold but only in cycling cells; 
increased apoptosis does not occur when K-ras
 
Val12
 
 is 
expressed alone or with a TAg containing 
 
Glu
 
107,108
 
®
 
Lys
 
107,108
 
 substitutions that block its ability 
to bind pRB. Analysis of bi-transgenic K-ras
 
Val12
 
 
 
3
 
 
TAg
 
Wt
 
 mice homozygous for wild-type or null p53 al-
leles established that the enhancement of apoptosis oc-
curs through a p53-independent mechanism, is not at-
tributable to augmented proliferation or to an increase 
in abortive cell cycle reentry (compared to TAg
 
Wt
 
 
mice), and is not associated with detectable changes in 
the crypt–villus patterns of expression of apoptotic reg-
ulators (Bcl-2, Bcl-x
 
L
 
, Bak, and Bax) or mediators of 
epithelial cell–matrix interactions and survival (e.g., 
 
a
 
5
 
b
 
1
 
 integrin and its ligand, fibronectin). Coexpression 
of K-ras
 
Val12
 
 and TAg
 
Wt
 
 produces dysplasia. The 
K-ras
 
Val12
 
-augmented apoptosis is unrelated to this dys-
plasia; enhanced apoptosis is also observed in cycling 
nondysplastic enterocytes that produce K-ras
 
Val12
 
 and a 
TAg with a COOH-terminal truncation. The dysplastic 
epithelium of K-ras
 
Val12
 
 
 
3
 
 TAg
 
Wt
 
 mice does not de-
velop neoplasms. Our results are consistent with this 
finding: (
 
a
 
) When expressed in initiated enterocytes 
with a proliferative abnormality, K-ras
 
Val12
 
 facilitates 
progression to a dysplastic phenotype; (
 
b
 
) by diminish-
ing cell survival on the villus, the oncoprotein may im-
pede further progression; and (
 
c
 
) additional mutations 
may be needed to suppress this proapoptotic response 
to K-ras
 
Val12
 
.
 
A
 
ctivating
 
 mutations of Ras genes are encountered in
 
z
 
30% of all human tumors and in 50% of colorec-
tal carcinomas (Bos et al., 1987; Forrester et al.,
1987; Fearon and Vogelstein, 1990). These mutations have
been generally described as early or intermediate events in
multistep journeys to neoplasia (Barbacid, 1987; Fearon
and Vogelstein, 1990). Studies of cultured cells have shown
that oncogenic forms of Ras can provoke premature se-
nescence or influence apoptosis—two responses that can
have an important impact on tumorigenesis.
Serrano et al. (1997) found that expression of an onco-
genic form of Ras in primary cultures of human and ro-
dent cells produces premature senescence, with perma-
nent arrest in G1. This effect is associated with an
induction of p53 as well as p16
 
INK4a
 
, the inhibitor of cyclin-
dependent kinase (cdk)
 
1
 
 4 and cdk6. The association is
causal rather than casual: inactivation of either p53 or p16
suppresses the senescence response to oncogenic Ras. The
implications of this finding to the origins of neoplasia are
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great (Serrano et al., 1997; for review see Weinberg, 1997).
p53 and/or p16 mutations are encountered in most human
tumors (Hollstein et al., 1994; Hirama and Koeffler, 1995).
Senescence can be viewed as a protective, antineoplastic
“host” response to an initial activating Ras mutation, a re-
sponse that can be overridden by subsequent inactivating
mutations of either p16 or p53, thereby allowing progres-
sion (transformation). This view fits with the multistep
model of human colorectal carcinoma, where early muta-
tion of Ras is followed by p53 inactivation (Fearon and
Vogelstein, 1990). The findings of Serrano and co-workers
also provide a rationale for two well-known phenomena:
(
 
a
 
) Primary cultures of embryonic cells are resistant to
transformation by oncogenic forms of Ras (Newbold and
Overell, 1983), while immortalized cells, which have often
acquired inactivating p16 or p53 mutations, are very sensi-
tive to transformation. (
 
b
 
) Oncogenic forms of Ras coop-
erate with viral oncoproteins, such as E1A or SV-40 large
T antigen (SV-40 TAg), to transform primary cell cultures.
Both of these viral proteins bind to and disable pRB, pro-
ducing an effect functionally analogous to p16 inactiva-
tion, since pRB is the principal substrate for phosphoryla-
tion by cdk4 and cdk6 (Weinberg, 1995, 1997). In the case
of SV-40 TAg, both pRB and p53 are bound and inacti-
vated.
Apoptosis represents another response that initiated
cells may marshal to prevent their amplification. Studies of
various established cultured cell lines have revealed that
oncogenic forms of Ras can affect apoptosis. Promotion as
well as suppression of cell death has been reported (Fer-
nandez et al., 1994; Chen and Faller, 1995; Kinoshita et al.,
1995; Lin et al., 1995; Rak et al., 1995; Wang et al., 1995).
Promotion of apoptosis in initiated cells should impede
their progression, while inhibition of apoptosis would be
expected to help facilitate tumorigenesis.
The effect of Ras oncoproteins on apoptosis or senes-
cence has not been examined using genetically defined in
vivo models. The impact of a lineage’s state of differentia-
tion and/or proliferative status on Ras-modulated demise
or survival can be assessed in transgenic mice where the
activated oncoprotein can be directed to selected target
cell populations. The self-renewing small intestinal epithe-
lium of the adult mouse represents an attractive system for
conducting such an analysis. Its attractiveness stems from
the fact that proliferation, differentiation, and death pro-
grams are continuously expressed in spatially well-defined
domains of crypt–villus units. Normally, these decisions
are precisely coordinated to maintain cellular census. Pro-
liferation is limited to crypts of Lieberkühn. Each crypt con-
tains one or more active multipotent stem cell located near
its base (Loeffler et al., 1993). The stem cell gives rise to
four principal epithelial cell lineages that complete their
terminal differentiation during a highly organized, rapid
migration. Postmitotic absorptive enterocytes, mucus-pro-
ducing goblet cells, and enteroendocrine cells exit the
crypt and move up an adjacent villus in vertical coherent
columns (Schmidt et al., 1985; Hermiston et al., 1996). Cells
are removed from the villus tip by apoptosis and/or extru-
sion into the lumen (Hall et al., 1994). The entire sequence
is completed in 3–5 d (Cheng, 1974
 
a
 
; Cheng and Leblond,
1974
 
a–c
 
). In contrast, members of the Paneth cell lineage
undergo terminal differentiation as they move down to the
base of the crypt, where they are subsequently removed
after an 
 
z
 
20-d residence (Cheng, 1974
 
b
 
). The availability
of lineage-specific promoters that function at selected lo-
cations along the crypt–villus units (e.g., Cohn et al., 1992;
Bry et al., 1994; Simon et al., 1995, 1997) makes it possible
to introduce activated Ras oncoproteins in specified cellu-
lar contexts and explore their effects on survival or death.
In the present report, we have used transgenic mice to
examine the effects of expressing human K-ras
 
Val12
 
 in post-
mitotic villus enterocytes. K-ras
 
Val12
 
 was also coexpressed
with wild-type or mutant SV-40 TAg’s that affect the pro-
liferative status of these cells. The results disclose that
K-ras
 
Val12
 
 can promote a p53-independent apoptosis that
occurs when enterocytes undergo pRB-related reentry
into the cell cycle.
 
Materials and Methods
 
Production and Maintenance of Transgenic Mice
 
FVB/N transgenic mice containing nucleotides 
 
2
 
1178 to 
 
1
 
28 of the rat
intestinal fatty acid–binding protein gene (
 
Fabpi
 
) linked to human
K-ras
 
Val12
 
, wild type (Wt) SV-40 TAg, SV-40 TAg
 
K107/8
 
 (mutant 3213 in Chen
et al., 1992), or SV-40 TAg
 
D
 
122
 
 
 
to
 
 
 
708
 
 (mutant dl1137 in Pipas et al., 1983) were
generated as described in earlier reports (Kim et al., 1993, 1994; Chan-
drasekaran et al., 1996). Transgenics were maintained by crosses to nor-
mal FVB/N littermates. Male and female C57Bl/6 p53
 
1
 
/
 
1
 
 and p53
 
2
 
/
 
2
 
 ani-
mals were purchased from GenPharm International (Mountain View, CA).
FVB/N 
 
Fabpi
 
–K-ras
 
Val12
 
 transgenic mice were crossed to FVB/N
 
Fabpi
 
–SV-40 TAg
 
Wt
 
, 
 
Fabpi
 
–SV-40 TAg
 
K107/8
 
, or 
 
Fabpi
 
–SV-40 TAg
 
D
 
122
 
 
 
to
 
 
 
708
 
animals to generate bi-transgenic mice. Animals were genotyped using tail
DNA and PCR protocols detailed elsewhere (Kim et al., 1993, 1994;
Chandrasekaran et al., 1996).
FVB/N normal, 
 
Fabpi
 
–K-ras
 
Val12
 
, 
 
Fabpi
 
–SV-40 TAg
 
Wt
 
, and 
 
Fabpi
 
–
K-ras
 
Val12
 
 
 
3
 
 
 
Fabpi
 
–SV-40 TAg
 
Wt
 
 transgenic mice homozygous for p53
wild-type or null alleles were generated by a series of crosses to C57Bl/6
p53
 
1
 
/
 
1
 
 and C57Bl/6 p53
 
2
 
/
 
2
 
 animals.
Mice were maintained in microisolator cages under a strict light cycle
(lights on at 0600 h and off at 1800 h). Animals were given a standard irra-
diated chow diet (Pico rodent chow 20; Purina Mills, Inc., St. Louis, MO)
ad libitum. Routine screens for Hepatitis, Minute, Lymphocytic Chorio-
meningitis, Ectromelia, Polyoma, Sendai, Pneumonia, and mouse adeno-
viruses, enteric bacterial pathogens, and parasites were negative.
 
Characterization of Transgenic Mice
 
Western Blots. 
 
Animals were sacrificed, and their gastrointestinal tracts
were removed en bloc. The small intestine was subdivided into thirds (de-
fined as duodenum, jejunum, and ileum). The distal half of the middle seg-
ment (“distal jejunum”) was snap frozen in liquid N
 
2
 
, lyophilized, pulver-
ized, and then resuspended in extraction buffer (50 
 
m
 
g lyophilized tissue/
ml buffer; extraction buffer 
 
5
 
 40 mM Tris, pH 6.8, 2% 2-mercaptoethanol,
1% SDS, 5% glycerol, 10 mM EDTA, 50 
 
m
 
g/ml aprotinin [Sigma Chemi-
cal Co., St. Louis, MO], 50 
 
m
 
g/ml leupeptin [Sigma Chemical Co.], 500 
 
m
 
g/ml
Pefabloc [Boehringer Mannheim Corp., Indianapolis, IN], and 10 
 
m
 
g/ml
pepstatin A [Sigma Chemical Co.]). Samples were boiled for 5 min, and
insoluble debris was removed by centrifugation for 3 min at 12,000 
 
g.
 
 The
protein concentration of the cleared supernatant was determined using
the DC Protein Assay kit (BioRad Labs., Hercules, CA). Extracted cellu-
lar proteins (75 
 
m
 
g/sample) were fractionated by SDS-PAGE (Laemmli,
1970) and electrophoretically transferred to polyvinylidene difluoride
membranes (Amersham Corp., Arlington Heights, IL). Membranes were
stained with Ponceau red to verify equivalent transfer of all samples. Blots
were pretreated in PBS-blocking buffer (1% gelatin, 0.2% Tween-20 in
PBS) for 1 h at 23
 
8
 
C and then incubated in blocking buffer for 2 h at 23
 
8
 
C
with: (
 
a
 
) affinity purified rabbit anti–Bcl-2 raised against a peptide span-
ning residues 4–21 of the mouse protein (Santa Cruz Biochemicals, Santa
Cruz, CA; final dilution in blocking buffer 
 
5
 
 1:500); (
 
b
 
) affinity-purified
rabbit anti-Bax raised against amino acids 11–30 of the mouse protein
(Santa Cruz Biochemicals; 1:500); (
 
c
 
) two preparations of affinity-purified
antibodies raised in rabbits against a peptide spanning residues 43–61 of 
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mouse Bax (obtained from Santa Cruz Biochemicals and from Stanley
Korsmeyer, Washington University School of Medicine; 1:500); (
 
d
 
) affinity-
purified rabbit antibodies against a peptide corresponding to amino acids
2–19 of mouse Bcl-x (Santa Cruz Biochemicals; 1:500); (
 
e
 
) affinity-purified
rabbit antibodies to residues 629–648 of mouse c-Raf-1 (Santa Cruz Bio-
chemicals; 1:500); (
 
f
 
) rabbit anti–mouse cdk4 (Santa Cruz Biochemicals; 1:
1,000); (
 
g
 
) rabbit anti–mouse cdk2 (Santa Cruz Biochemicals; 1:1,000); (
 
h
 
)
mouse SV-40 TAg mAbs (1:1,000; PharMingen, San Diego, CA); (
 
i
 
) rab-
bit antiactin (Sigma Chemical Co.; 1:5,000); and (
 
j
 
) rabbit anti–rat liver
fatty acid binding protein (L-Fabp; Sweetser et al., 1988; 1:7,000). Anti-
gen–antibody complexes were visualized with alkaline phosphatase-conju-
gated secondary antibodies and a chemiluminescent substrate using the
Western Light
 
®
 
 kit (Tropix, Inc., Bedford, MA). All experiments were
performed using three to eight animals/genotype and repeated on two to
six occasions.
Blocking controls were performed by preincubating antibodies with a
10-fold weight excess of their corresponding peptide antigens for 1 h at
23
 
8
 
C before probing the blots. In addition, the specificity of the Bax anti-
body preparations was established by probing Western blots containing
proteins extracted from the distal jejunum, spleen, and thymus of mice
that were homozygous for wild-type or null alleles of the Bax gene (tissues
obtained from S. Korsmeyer; Knudson et al., 1995).
 
Immunohistochemical Analysis of the Expression of 
Regulators of the G1/S Transition and of Apoptosis
 
Postnatal day 42 to 60 (P42–60) male and female FVB/N mice containing
one or two transgenes and their normal littermates (
 
n
 
 
 
5
 
 10 animals/geno-
type) were given an intraperitoneal injection of 5-bromo-2
 
9
 
deoxyuridine
(BrdU; Sigma Chemical Co.; 120 mg/kg body weight) and 5-fluoro-2
 
9
 
-deoxy-
uridine (Sigma Chemical Co.; 12 mg/kg) 90 min before sacrifice to label
cells in S-phase. The small intestine was removed, flushed with PBS, fixed
in Bouin’s solution for 6–12 h, washed with 70% ethanol, and then divided
into proximal and distal halves. Each half was opened with an incision
along its cephalocaudal axis and then rolled from its proximal to distal
end. Each of the resulting “Swiss rolls” was then cut in half parallel to the
duodenal–ileal axis and placed in a tissue cassette with the cut edge of one
half facing down and the cut edge of the other half facing up. After em-
bedding in paraffin, serial 5-
 
m
 
m-thick sections were prepared. Alterna-
tively, small intestine was fixed in 10% buffered formalin (Baxter Heath-
core Corp., Mundelein, IL) for 4 h and processed as above.
All immunohistochemical manipulations were performed using the Mi-
croProbe system (Fisher Biotech, Chicago, IL). Bouin’s- or formalin-fixed
sections were deparaffinized in xylene and isopropanol and were then
subjected to an antigen unmasking protocol consisting of a 4-min incuba-
tion at 37
 
8
 
C in type II bovine pancreas 
 
a
 
-chymotrypsin (Sigma Chemical
Co.; specific activity 
 
5
 
 50 U/mg; final concentration 
 
5
 
 1 mg enzyme/ml of
7 mM CaCl
 
2
 
, pH 7.8). The treated sections were washed in PBS, placed in
histo-blocking buffer (BSA [1% wt/vol], Triton X-100 [0.3%], powdered
skim milk [0.2%] in PBS) for 15 min at 23
 
8
 
C followed by an overnight in-
cubation at 4
 
8
 
C with: (
 
a
 
) two different preparations of rabbit anti–mouse
Bcl-2; one was the peptide-specific antibody described above (1:50), the
other was raised against a glutathione S–transferase fusion protein con-
taining amino acids 1–205 of human Bcl-2 (1:100; Santa Cruz Biochemi-
cals); (
 
b
 
) rabbit anti–mouse Bcl-x (see above; 1:500); (
 
c
 
) two different
preparations of affinity-purified rabbit antibodies raised against amino ac-
ids 43–61 of the mouse Bax (see above; 1:500); (
 
d
 
) mouse mAbs to Bak
that react with the orthologous mouse and human proteins (Calbiochem,
La Jolla, CA; 1:100); (
 
e
 
) affinity-purified c-Raf antibodies (see above; 1:
500); (
 
f) rabbit anti–mouse pRB (Santa Cruz Biochemicals; 1:500); (g)
rabbit anti–mouse cyclin D1 (Upstate Biotechnology, Inc., Lake Placid,
NY; 1:100); (h) anti–mouse cdk4 (see above; 1:500); (i) rabbit anti–mouse
cyclin E (Santa Cruz Biochemicals; 1:500); (j) anti–mouse cdk2 (see above;
1:500); (k) goat anti–BrdU sera (Cohn and Lieberman, 1984; 1:1,000); (l)
mouse mAb against subunit I of human cytochrome oxidase (5D4-F5; Mo-
lecular Probes, Eugene, OR; 1:100); and (m) rabbit anti–SV-40 TAg (ob-
tained from Doug Hanahan, University of California, San Francisco, CA;
1:1,000). Formalin-fixed tissues were used to identify Bcl-2, Bax, Bak, Bcl-x,
c-Raf-1, pRB, cyclin D1, cdk4, cdk2, and cytochrome oxidase subunit I.
BrdU and cyclin E expression were surveyed in Bouin’s-fixed tissues.
Antigen–antibody complexes were detected using indocarbocyanine
(Cy3)-labeled donkey anti–rabbit Ig (Jackson ImmunoResearch, West
Grove, PA; 1:500), FITC-labeled donkey anti–goat Ig (Jackson Immu-
noResearch; 1:100); Cy3-sheep anti–mouse Ig (Jackson ImmunoResearch;
1:500), or FluorX-conjugated donkey anti–mouse IgG (Biological Detec-
tion Systems, Amersham Life Sciences, Arlington, IL; 1:200). Nuclei were
stained with bis-benzimide (Sigma Chemical Co.; 0.05 mg/ml PBS). Block-
ing controls were performed by preincubating the primary antibodies with
their peptide antigens overnight at 48C before application to tissue sec-
tions.
Immunohistochemical Analysis of the Crypt–Villus 
Pattern of Expression of Integrins and Their Ligands 
Using Tyramide Signal Amplification
The spatial distribution of these proteins was examined in P42–60 normal
and transgenic mice (n 5 2–4 animals/group) using the following panel of
antibodies: (a) rat anti–mouse b1 integrin mAb (clone 9EG7; PharMin-
gen, San Diego, CA; diluted 1:2,000); (b) rabbit anti–mouse a3 integrin
(Chemicon, Temecula, CA; 1:4,000); (c) rabbit anti–mouse a5 integrin
(Chemicon; 1:2,000); (d) rat anti–human/mouse a6 mAb (clone GoH3,
PharMingen; 1:4,000) (e) rat anti–mouse b4 mAb (clone 346-11A; Phar-
Mingen; 1:2,000); (f) rabbit anti–mouse fibronectin (Chemicon; 1:5,000);
(g) rabbit anti–mouse laminin (recognizes both A and B laminin isoforms;
Chemicon; 1:5,000); and (h) rabbit anti–mouse type IV collagen (Chemi-
con; 1:5,000).
Mice were sacrificed, and the middle third of the small bowel was
flushed with PBS and then frozen in OCT (Miles, Inc., Kanakee, IL). Se-
rial 5-mm-thick sections were cut, fixed in methanol (2208C for 15 min),
washed three times (3 min/cycle) in PBS, and treated with PBS-blocking
buffer for 15 min at room temperature. Cells with endogenous peroxidase
activity were labeled by incubating the frozen sections for 10 min at room
temperature with FITC-conjugated biotinyl-tyramide (New England Nu-
clear Life Sciences, Boston, MA; diluted 1:100 in 13 amplification diluent
from the same manufacturer). After three washes in PBS (5 min each), the
sections were incubated overnight at 48C with one of the primary antibod-
ies listed above and then washed in TNT buffer (0.1 M Tris, pH 7.5/0.15 M
NaCl/0.05% Tween-20; 3 cycles; 5 min each). HRP-conjugated goat anti–
rat or goat anti–rabbit Ig were added (Kirkegaard and Perry Labs, Gaith-
ersburg, MD; diluted 1:100 in TNB buffer [0.1 M Tris, pH 7.5/0.15M NaCl/
0.5% blocking reagent from New England Nuclear Life Sciences]). After
a 30-min incubation at room temperature, sections were washed three
times with TNT buffer (5 min each). Biotinyl-tyramide was added (diluted
1:100 in 13 amplification diluent) for 10 min. Sections were washed three
times in TNT buffer (5 min/cycle), subsequently overlaid with Cy3-conju-
gated streptavidin (New England Nuclear Life Sciences; diluted 1:500 in
TNB) for 30 min, and then subjected to three more rinses in TNT buffer
before coverslips were added.
Two controls were performed for each experiment using a given pri-
mary antiserum: direct amplification of endogenous peroxidase activity
alone (see above) and omission of primary antibodies.
Quantitation of Apoptosis
Terminal deoxynucleotidyltransferase (TdT)–mediated, dUTP nick end
labeling (TUNEL) assays were performed on sections of formalin-fixed
Swiss rolls using the protocol of Gavrieli et al. (1992), except that sections
were incubated with proteinase K (Boehringer Mannheim Corp.; 20 mg/ml)
for 20 min at 238C. Incorporation of digoxigenin-labeled dUTP was de-
tected using peroxidase-conjugated sheep anti–digoxigenin Fab fragments
(Boehringer Mannheim Corp.; diluted 1:500 in PBS-blocking buffer) and
the Vector VIP kit (Vector Laboratories, Burlingame, CA). Sections were
counterstained in methyl green (Zymed Labs, S. San Francisco, CA).
The number of TUNEL-positive epithelial cells with apoptotic mor-
phology (Wyllie et al., 1980, Hall et al., 1994) were scored in a blinded
fashion by two observers. All intact crypt–villus units present in two non-
adjacent sections of a Swiss roll prepared from the distal half of the small
intestine were surveyed (n 5 3–5 animals/genotype). Statistical analyses
were performed using Student’s t test (SigmaPlot; Jandel Corp., San
Rafael, CA).
Quantitation of the Ratio of S-phase to M-phase Cells
The small intestine was removed from single transgene-containing and bi-
transgenic mice that had been pulse-labeled 90 min before sacrifice with
BrdU. Jejunal segments were fixed in Bouin’s, embedded in paraffin, and
serial 5-mm sections were stained with hematoxylin and eosin or with anti-
bodies to BrdU. M-phase and S-phase cells in crypts and villi wereThe Journal of Cell Biology, Volume 138, 1997 170
counted in adjacent serial sections. 40 well-oriented crypt–villus units
were scored per section (n 5 2 sections/mouse; 3 mice/genotype).
Measurements of K-rasVal12 mRNA Levels
Total cellular RNA was isolated from the jejunum of single transgene-
containing animals, bi-transgenic mice, and normal littermates. K-rasVal12
mRNA levels were defined using a ribonuclease protection assay (Kim et al.,
1993). The 199 base cRNA yields a 148 base protected fragment when an-
nealed to the mRNA product of Fabpi–K-rasVal12 and a 54 base protected
fragment when annealed to the mRNA product of the endogenous mouse
c-K-rasGly12 gene.
Results
Studies of Bi-transgenic Mice Indicate That K-rasVal12 
Augments the p53-independent Apoptosis Produced by 
SV-40 TAgWt in Villus Enterocytes
We examined the effect of an activated Ras, human K-rasVal12,
on apoptosis in villus enterocytes of transgenic mice.
K-rasVal12 was selected because it is the most common acti-
vated Ras found in intestinal neoplasms (Bos et al., 1987;
Forrester et al., 1987).
Studies in transgenic mice have shown that nucleotides
21178 to 128 of the rat intestinal fatty acid binding pro-
tein gene (Fabpi) can be used to restrict expression of for-
eign gene products to postmitotic villus enterocytes dis-
tributed along the length of the small intestine (e.g., Cohn
et al., 1992; Kim et al., 1993; Hermiston et al., 1996). Trans-
gene expression is activated just as enterocytes emerge
from the crypt and is sustained as they complete their up-
ward migration to the villus’ apical extrusion zone. Fabpi–
reporter transgenes are first expressed coincident with the
initial cytodifferentiation of the intestinal epithelium on
embryonic day 15. Expression is maintained for at least
the first 2 yr of life.
Ribonuclease protection assays indicated that like other
Fabpi21178 to 128-containing transgenes, Fabpi–K-rasVal12 is
expressed at highest levels in the middle third of the small
intestine (jejunum) of 6–8-wk-old FVB/N mice (data not
shown).
Quantitative TUNEL and morphologic assays of apop-
tosis in P42–60 Fabpi–K-rasVal12 transgenic mice and their
normal littermates revealed that production of K-rasVal12
Figure 1. Quantitative analy-
sis of apoptosis in the jejunal
villus  epithelium of adult
transgenic and bi-transgenic
mice homozygous for p53
wild-type or null alleles. (A)
Postnatal day (P) 42 p531/1
FVB/N transgenic mice. (B)
P42 p532/2 animals with
equivalent genetic back-
grounds. An asterisk indi-
cates that the results ob-
tained for animals of this
genotype are significantly
different from normal litter-
mate controls (P , 0.05).
Crypt apoptosis was not sig-
nificantly different between
normal nontransgenic ani-
mals and any of the single
transgene-containing or bi-
transgenic mice (data not
shown).
Figure 2. Expression of cdk2 in FVB/N normal, transgenic, and bi-transgenic mice. (A) Western blot of jejunal protein extracts (75 mg/
lane) prepared from P42 mice, probed with affinity-purified antibodies to cdk2. Lane 1, nontransgenic FVB/N mouse; lane 2, Fabpi–K-
rasVal12 animal; lane 3, Fabpi–SV-40 TAgWt mouse; lane 4, K-rasVal12 3 SV-40 TAgWt bi-transgenic animal; lane 5, K-rasVal12 3 SV-40
TAgK107/8 bi-transgenic mouse. (B–D) Expression of cdk2 along jejunal crypt–villus units of a P42 normal FVB/N mouse (B), a Fabpi–
SV-40 TAgWt transgenic littermate (C), and a P42 K-rasVal12 3 SV-40 TAgWt bi-transgenic mouse (D). Cdk2 was detected by incubating
the tissue sections with the same rabbit anti–mouse cdk2 preparation used for the Western blotting experiment shown in A and Cy3-
conjugated donkey anti–rabbit Ig. Cdk2 (red) is confined to proliferating crypt epithelial cells in the normal FVB/N mouse. (The closed
arrows in B point to a crypt–villus junction; the open arrow points to a crypt base columnar epithelial cell. These cells represent prolifer-Coopersmith et al. K-rasVal12 and Intestinal Epithelial Apoptosis 171
ating precursors of the enterocytic lineage and are intermixed with differentiated Paneth cells at the base of crypts [Cheng and Leblond,
1974a].) SV-40 TAgWt expression is associated with an induction of cdk2 in villus enterocytes (e.g., C, arrow). A similar induction of
cdk2 in villus enterocytes is evident in the bi-transgenic animal (D). (E–G) Multilabel immunohistochemical study of a jejunal crypt–vil-
lus unit from the bi-transgenic mouse shown in D, establishing that villus enterocytes have reentered the cell cycle. The mouse received
an intraperitoneal injection of BrdU 1.5 h before sacrifice. The section was stained with rabbit anti–SV-40 TAg (visualized in E with
Cy3-donkey anti–rabbit Ig) and goat anti-BrdU (visualized in F with FITC-conjugated donkey anti–goat Ig). G is a dual exposure of the
section confirming that BrdU-positive cells distributed along the length of the villus also express SV-40 TAgWt (yellow-orange staining
nuclei). The closed arrows in E–G indicate the location of the crypt–villus junction. The open arrows in G point to proliferating crypt ep-
ithelial cells that do not express SV-40 TAgWt. (Fabpi–directed expression of SV-40 TAgWt is limited to villus enterocytes.) Bar, 25 mm.The Journal of Cell Biology, Volume 138, 1997 172
in jejunal villus enterocytes produces no statistically signif-
icant change in their basal level of apoptosis (Fig. 1 A).
This is true whether animals are p531/1 or p532/2 (Fig. 1,
A and B). Apoptotic cells are limited to the tips of villi in
both  Fabpi–K-rasVal12 animals and their nontransgenic
FVB/N cagemates.
Forced expression of K-rasVal12 has no detectable effect
on the pattern of accumulation of regulators of the G1/S
transition of the cell cycle. Terminal differentiation of nor-
mal FVB/N enterocytes is associated with rapid loss of cy-
clin D1 and cdk2 but not their partners, cdk4 and cyclin E.
Cellular levels of pRB do not change as enterocytes move
from the base to the tips of villi, although pRB phosphory-
lation appears to diminish (Chandrasekaran et al., 1996).
Immunohistochemical and Western blot analyses of nor-
mal and transgenic mouse intestine revealed that K-rasVal12
does not affect expression of these cell cycle regulators
(Fig. 2 A, plus data not shown), nor does it cause villus
enterocytes to reenter the cell cycle, whether judged by
their ability to incorporate BrdU or by the appearance of
M-phase cells (data not shown).
Other markers of terminal differentiation of the entero-
cytic lineage, including a complex pattern of glycoconju-
gate production defined by in situ binding of members of a
panel of lectins to fixed sections of intestine (Falk et al.,
1994; Hermiston and Gordon, 1995), are unaffected by
K-rasVal12 (data not shown).
Fabpi-directed expression of SV-40 TAgWt in villus en-
terocytes induces cyclin D1 and cdk2 expression and
causes cell cycle reentry (Chandrasekaran et al., 1996).
SV-40 TAgWt-induced reentry is accompanied by a statisti-
cally significant threefold increase in villus epithelial cell
apoptosis (P , 0.05; Fig. 1 A). Apoptotic cells are present
in the lower and mid-portion of Fabpi–SV-40 TAgWt villi,
regions where apoptotic events are undetectable in normal
FVB/N littermates (data not shown).
Crossing FVB/N Fabpi–K-rasVal12 mice to FVB/N Fabpi–
SV-40 TAgWt mice yields bi-transgenic animals with a pro-
liferating and dysplastic population of enterocytes. The
dysplasia is manifested in part by branched villi (Fig. 3 A).
K-rasVal12 augments the apoptosis observed in SV-40
TAgWt–positive villus enterocytes; bi-transgenic mice have
a statistically significant threefold increase in apoptotic
cells in jejunal villi compared to Fabpi–SV-40 TAgWt trans-
genics, and a statistically significant six- to ninefold in-
crease when compared to mice containing Fabpi–K-rasVal12
alone or no transgenes (Fig. 1 A). Apoptotic cells are evi-
dent in the lower and middle thirds of villi and occur in re-
gions with and without dysplasia (Fig. 3, A–D).
The augmented apoptosis in bi-transgenic mice cannot
be attributed to alterations in K-rasVal12 or SV-40 TAg ex-
pression. Ribonuclease protection assays indicated that
K-rasVal12 mRNA levels are equivalent in jejunal RNAs
isolated from animals containing Fabpi–K-rasVal12 alone or
Fabpi–K-rasVal12 and Fabpi–SV-40 TAgWt. SV-40 TAgWt
mRNA levels are also indistinguishable in Fabpi–SV-40
TAgWt transgenic and K-rasVal12 3 SV-40 TAgWt bi-trans-
genic animals (data not shown).
The steady-state levels plus intracellular and crypt–vil-
lus distributions of pRB, cyclin D1, cyclin E, cdk4, and
cdk2 are the same in Fabpi–SV-40 TAgWt and K-rasVal12 3
SV-40 TAgWt animals. In addition, there is no statistically
significant difference in the ratio of S-phase to M-phase
cells in the jejunal villi of bi-transgenic K-rasVal12 3 SV-40
TAgWt mice compared to their Fabpi–SV-40 TAgWt litter-
mates (Fig. 2, A–G, plus data not shown). These results in-
dicate that the K-rasVal12 effect on apoptosis is not due to
increases in either proliferation or abortive cell cycle reentry.
K-rasVal12 Can Only Augment Apoptosis When SV-40 
TAg Is Able to Produce Cell Cycle Reentry
SV-40 TAgK107/8 is a mutant with Lys for Glu substitutions
at residues 107 and 108. These substitutions block the abil-
ity of TAg to bind pRB and the related pocket proteins
p107 and p130 but do affect p53 binding (Fanning and
Knippers, 1992). (p107 and p130 are not detectable in the
small intestinal epithelium of adult FVB/N mice using com-
mercially available antibodies and a variety of sensitive
immunohistochemical detection methods [Chandraseka-
ran et al., 1996].) We analyzed adult (6–8-wk-old) FVB/N
Fabpi–SV-40 TAgK107/8 transgenic mice with equivalent
concentrations of TAg in their total jejunal protein ex-
tracts as our Fabpi–SV-40 TAgWt animals (Chandraseka-
ran et al., 1996). Expression of the mutant TAg in villus
enterocytes does not induce cyclin D1 or cdk2, does not
cause reentry into the cell cycle, and does not cause any
significant increase in apoptosis compared to normal lit-
termate controls (Fig. 1 A, plus data not shown). Coex-
pression of K-rasVal12 and SV-40 TAgK107/8 in bi-transgenic
mice does not change the growth-arrested state of villus
enterocytes, as judged by their lack of incorporation of
BrdU, by the lack of cells in M-phase, and by the lack of
detectable changes in the steady-state levels or crypt–vil-
lus distributions of pRB, cyclins D1 and E, and their part-
ners cdk4 and cdk2 (e.g., compare lanes 1 and 5 in Fig. 2 A).
There are no dysplastic changes in the small intestinal epi-
thelium of these animals (n 5 15). Moreover, K-rasVal12 3
SV-40 TAgK107/8 mice do not manifest any significant in-
creases in villus apoptosis when compared to nontrans-
genic FVB/N animals or FVB/N mice containing either
one of the transgenes alone (Fig. 1 A).
p53 Is Not Required
A comparison of the phenotypes of K-rasVal12 3 SV-40
TAgK107/8 and K-rasVal12 3 SV-40 TAgWt mice establishes
a linkage between pRB and the observed apoptotic re-
sponse of villus enterocytes. It also indicates that func-
tional domains of the viral oncoprotein, other than its pRB
binding region, are not sufficient to induce death in villus
enterocytes or to mediate the further enhancement of
apoptosis by K-rasVal12. An analysis of cell death in the
jejunal crypt–villus units of 6–8-wk-old p531/1 and p532/2
K-rasVal12 3 SV-40 TAgWt mice provided definitive proof
that K-rasVal12 augments apoptosis through a p53-indepen-
dent pathway (Fig. 1, A and B).
The Presence or Absence of Dysplasia Has Little Effect 
on the Ability of K-ras to Increase Apoptosis in Cycling 
Villus Enterocytes
SV-40 TAgD122 to 708 is a truncation mutant that contains
the NH2-terminal 121 residues of the viral oncoprotein. It
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but does not interact with p53 (Srinivasan et al., 1989). We
examined members of a pedigree of FVB/N Fabpi–SV-40
TAgD122 to 708 mice whose jejunal TAg levels were equiva-
lent to those observed in FVB/N Fabpi–SV-40 TAgWt and
Fabpi–SV-40 TAgK107/8 animals. Cdk2 is induced in the vil-
lus enterocytes of Fabpi–SV-40 TAgD122 to 708 mice. Reen-
try into the cell cycle occurs, although the proliferative re-
sponse is less than what is observed with SV-40 TAgWt
(e.g., the steady-state concentrations of cdk2 in jejunal pro-
tein extracts are 50–60% of those in age-matched Fabpi–
SV-40 TAgWt animals; n 5 3 mice/genotype). Coexpression
of K-rasVal12 and the truncation mutant does not produce
dysplasia in jejunal villi (Kim et al., 1994). Nonetheless,
coexpression results in a statistically significant (P , 0.05)
2.3-fold increase in apoptosis compared to age-matched
Fabpi–SV-40 TAgD122 to 708 cagemates (Fig. 1 A).
Coexpression of K-rasVal12 and SV-40 TAgWt Has No 
Appreciable Effect on the Crypt–Villus Distribution or 
Steady-State Levels of Bcl-2, Bcl-xL, Bak, Bax,
and c-Raf-1
Previous studies of the effect of Ras oncoproteins on apop-
tosis in a variety of cultured cell lines implicated Bcl-2 and/
or p53 as mediators (Fernandez-Sarabia and Bischoff,
1993; Tanaka et al., 1994; Chen and Faller, 1995, 1996; Ki-
noshita et al., 1995; Lin et al., 1995; Wang et al., 1995).
Therefore, the distribution of several regulators of apopto-
sis were analyzed along the jejunal crypt–villus units of
normal FVB/N mice and in littermates containing all com-
binations of the transgenes described above. Bak (bcl-2
homologous antagonist/killer) is proapoptotic (Chittenden
et al., 1995; Farrow et al., 1995; Kiefer et al., 1995). Bcl-2 is
Figure 3. Distribution of apoptotic cells in jejunal villi of a P42 K-rasVal12 3 SV-40 TAgWt bi-transgenic animal. (A) Villus section
stained with hematoxylin and eosin. The arrow points to a branch. Such branching is not seen in normal villi. (B) High power view of the
boxed region in A. The closed arrow points to an apoptotic cell. (C and D) Apoptotic cells, whether defined by histologic criteria (C, ar-
rows) or by the TUNEL assay (e.g., D, arrow), are numerous and distributed in the middle (as well as lower and upper) third of villi.
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an antiapoptotic (Bakhshi et al., 1985; Cleary and Sklar,
1985; Tsujimoto et al., 1985). Alternative splicing of the
Bcl-x gene gives rise to Bcl-xL, which is antiapoptotic, and
Bcl-xS, which is proapoptotic (Boise et al., 1993; N.B.
Western blots indicate that Bcl-xL represents .95% of to-
tal jejunal Bcl-x in normal and bi-transgenic animals; data
not shown).
Differentiation of the enterocytic lineage is normally as-
sociated with an upregulation of Bcl-2 and Bcl-xL without
appreciable expression of Bak. The increased apoptosis
seen along the length of SV-40 TAgWt, K-rasVal12 3 SV-40
TAgWt, and K-rasVal12 3 SV-40 TAgD122 to 708 jejunal villi is
not associated with any remarkable change in the cellular
or intracellular patterns of accumulation of these proteins.
Figure 4. Cellular and intra-
cellular distributions of Bak,
Bcl-2, Bcl-xL, and c-Raf-1 in
jejunal crypt–villus units of
P42 bi-transgenic K-rasVal12
3 SV-40 TAgWt mice. (A)
Section of a crypt stained
with mouse monoclonal anti-
bodies to Bak and Cy3-sheep
anti–mouse Ig. The open ar-
rows point to a crypt–villus
junction. The apical surfaces
of crypt epithelial cells are
intensely stained (closed ar-
row). Bak falls to undetect-
able levels as postmitotic en-
terocytes emerge from the
crypt and enter the lower
quarter of the villus. The
open arrowhead points to
one of several lamina propria
lymphocytes that react with
secondary Cy3-conjugated
sheep antibodies to mouse Ig.
(B–F) Distribution of the
antiapoptotic mediator Bcl-2.
(B) Section of a bi-transgenic
jejunal villus stained with af-
finity-purified rabbit anti–
Bcl-2 plus Cy3-donkey anti–
rabbit Ig. (C) Same section
stained as in B but with a nu-
clear stain (bis-benzimide;
blue). (D) Blocking control
in which the primary anti-
body was incubated with the
peptide antigen from which it
was generated, before appli-
cation to another jejunal
crypt–villus unit. (E) Same
section as shown in B and C,
stained with mouse mAbs
against cytochrome oxidase
subunit I, a mitochondrial
protein, and FluorX-conju-
gated donkey anti–mouse Ig.
(F) A triple exposure of C
and  E. Bcl-2 is barely detectable in the central portion of crypts where the proliferating transit cell population resides or at the crypt
base were Paneth cells are located (data not shown). Cellular levels rise markedly just as enterocytes exit the crypt. There is no appre-
ciable change in steady-state concentration or intracellular distribution of Bcl-2 as enterocytes complete their migration up the villus.
The distribution of Bcl-2 within enterocytes is similar to the distribution of the mitochondrial marker, consistent with its previously de-
scribed organelle affiliation in other cell lineages (Hockenbery et al., 1990). (G–I) Antibodies to Bcl-x produce a crypt–villus and intra-
cellular pattern of staining that mimics that of Bcl-2. G is a section of a bi-transgenic jejunal villus incubated with affinity-purified rabbit
anti–Bcl-x, Cy3-donkey anti–rabbit Ig, and bis-benzimide. H shows the same section stained with mouse mAbs to subunit I of cyto-
chrome oxidase and FluorX-conjugated donkey anti–mouse Ig. I is a triple exposure. (J) Jejunal villus from a bi-transgenic mouse
stained with affinity-purified rabbit anti–c-Raf-1 and Cy3-donkey anti–rabbit Ig. c-Raf is expressed in epithelial cells distributed
throughout the length of jejunal crypt–villus units. Cellular levels do not change appreciably as cells complete their migration-associated
terminal differentiation. Immunoreactive protein is absent from the nucleus and present throughout the cytoplasm, where it produces a
granular pattern of staining. Bars, 25 mm.Coopersmith et al. K-rasVal12 and Intestinal Epithelial Apoptosis 175
Bak remains confined to the crypt and is not induced in cy-
cling villus enterocytes (Fig. 4 A). Bcl-2 remains undetect-
able or barely detectable in crypt epithelial cells, continues
to be induced at the crypt–villus junction, and is not sup-
pressed as cells move to the villus tip, even though they are
dividing (Fig. 4, B–I). The crypt–villus and intracellular
distributions of Bcl-xL are similar to those of Bcl-2 in all
cases (e.g., compare G–I with C, E, and F in Fig. 4). West-
ern blots of jejunal extracts prepared from transgenic and
bi-transgenic mice established that expression of K-rasVal12,
SV-40 TAgWt, SV-40 TAgK107/8, or SV-40 TAgD122 to 708
alone, or K-rasVal12 plus the various SV-40 TAgs, has no
appreciable effects on the steady state levels of Bcl-2, Bcl-xL,
or the proapoptotic mediator Bax (Oltvai et al., 1993)
(Fig. 5).2
Recent studies of cultured cells suggest that c-Raf-1, a
serine-threonine kinase that plays a central role in the mi-
togen-activated kinase signaling pathway, may also oper-
ate downstream of Ras and upstream of Bcl-2 to promote
death (Wang et al., 1994; Blagosklonny et al., 1996). Coex-
pression of K-rasVal12 and SV-40 TAgWt does not perturb
the cellular patterns of c-Raf-1 accumulation (Fig. 4 J) or
the steady-state level of this protein (Fig. 5).
Expression of SV-40 TAgWt and K-rasVal12 Does Not 
Have a Detectable Affect on the Crypt–Villus Patterns 
of Accumulation of Integrins or Their Ligands
Depending upon the cell type, interactions with extracellu-
lar matrix (ECM) can either promote anchorage-depen-
dent growth or signal cell cycle arrest and terminal differ-
entiation (Lin and Bissell, 1993). Anoikis refers to the
propensity of cultured (epithelial or endothelial) cells to
undergo apoptosis when dissociated from extracellular
matrix (Meredith et al., 1993; Frisch and Francis, 1994; for
review see Ruoslahti and Reed, 1994). Integrins have been
implicated as mediators of these responses to the ECM
(Meredith et al., 1993; Boudreau et al., 1995; Zhang et al.,
1995; Pullan et al., 1996; Wary et al., 1996; Frisch et al.,
1996). A Ras-linked MAP kinase pathway has been identi-
fied recently that functions to reduce the affinity of some
integrins for their ligands (Hughes et al., 1997).
It is possible that cycling SV-40 TAgWt–positive villus
enterocytes or dysplastic K-rasVal12 3 SV-40 TAgWt en-
terocytes have altered interactions with the ECM and that
such alterations curtail their survival; after all, apoptosis is
normally limited to the same apical region of the villus
where cells detach from the matrix (and from one an-
other) and are exfoliated into the lumen (Hall et al., 1994).
Therefore, we used sensitive immunohistochemical detec-
tion methods (i.e., tyramide signal amplification; Bobrow
et al., 1989; Shindler and Roth, 1996) to analyze the effects
of expressing K-rasVal12, SV-40 TAgWt, or both oncopro-
teins on the crypt–villus distributions of integrins associ-
ated with the regulation of epithelial cell growth and sur-
vival (a5b1) and with intestinal epithelial cell adhesion to
the ECM (a6b4) (Giancotti and Ruoslahti, 1990; Mortarini
et al., 1992; Ruoslahti and Reed, 1994; Simon-Assmann et al.,
1994; Zhang et al., 1995).
In normal FVB/N mice, a5, a6, b1, and b4 integrin sub-
units accumulate at the base of all epithelial cells in crypt–
villus units (Fig. 6, A, E, H, L, and M). a3, another b1 part-
ner, is limited to the basal surface of villus epithelial cells
(data not shown). These patterns are not perturbed in
Fabpi–K-rasVal12 or Fabpi–SV-40 TAgWt animals or in
their bi-transgenic littermates (n 5 2–4 animals/genotype;
Fig. 6, A–O).
VLA5 (a5b1) and VLA3 (a3b1) function as receptors for
fibronectin. In nontransgenic FVB/N mice, fibronectin is
distributed in the ECM from the crypt base to the villus tip
(Fig. 6 P). Expression of K-rasVal12 or SV-40 TAgWt, alone
Figure 5. Western blot analysis of the steady-state levels of Bcl-2,
Bcl-xL, Bax, and c-Raf-1 in jejunal extracts prepared from P42
FVB/N normal, transgenic, and bi-transgenic animals. Total jeju-
nal proteins (75 mg/lane) were fractionated by SDS-PAGE. Rep-
licate protein blots were probed with antibodies to regulators of
apoptosis or liver fatty acid–binding protein (L-Fabp; an entero-
cytic marker). (A) Lane 1, extract from a Fabpi–K-rasVal12 mouse;
lane 2, extract from a Fabpi–SV-40 TAgWt mouse; lane 3, extract
from a bi-transgenic K-rasVal12 3 SV-40 TAgWt animal. (B) Lane 1,
normal FVB/N mouse; lane 2, Fabpi–SV-40 TAgWt animal; lane
3, bi-transgenic K-rasVal12 3 SV-40 TAgWt mouse. The results
shown are representative of those obtained with three to eight
animals/genotype.
2. Three different preparations of Bax antibodies, two raised against a
peptide spanning residues 43–61 of the protein and the other against resi-
dues 11–30, yielded the expected patterns of reactivity with jejunal,
spleen, and thymic proteins prepared from mice homozygous for wild-
type or null alleles of Bax; a 21-kD protein was detected in Bax1/1 tissue
extracts but was absent from Bax2/2 extracts. Affinity-purified polyclonal
antibodies against residues 11–30 failed to detect Bax in sections of jejunal
crypt–villus units prepared from Bax1/1 or Bax2/2 animals. However,
both preparations of antibodies to residues 43–61 produced similar pat-
terns of staining in Bax2/2 and Bax1/1 animals, whether jejunal sections
were fixed in Bouin’s solution or formalin and whether or not antigen un-
masking protocols were used. In all cases, staining was blocked by prein-
cubation of the antibody with the Bax peptide before its application to tis-
sue sections. Immunoreactive Bax, or what is presumed to be a protein
with a shared epitope, is present at low levels in epithelial cells distributed
from the base to the tip of villi. The protein(s) are undetectable in the up-
per and middle thirds of the crypt. However, long-lived Paneth cells lo-
cated at the crypt base are intensely stained (data not shown).The Journal of Cell Biology, Volume 138, 1997 176
Figure 6. Immunohistochemical analysis of the crypt–villus pattern of accumulation of integrin subunits and their ligands in 6-wk-old
FVB/N normal, transgenic, and bi-transgenic mice. Frozen sections of jejunum were processed as described in Materials and Methods.
The top of each panel is labeled to show the protein that is being examined. The bottom of each panel gives the genotype of the mouse.
Antigen–antibody complexes were detected using HRP-conjugated secondary antibodies, biotinyl tyramide amplification, and Cy3-
streptavidin. Integrin subunits and integrin ligands appear red-orange. Cells that contain endogenous peroxidase activity were colabeled
with FITC–biotinyl tyramide and Cy3-streptavidin and appear yellow-green. nl, normal (nontransgenic) FVB/N mouse; K-ras, litter-
mate containing the Fabpi–K-rasVal12 transgene; TAg, Fabpi–SV-40 TAgWt transgenic animal; K-ras 3 TAg, Fabpi–K-rasVal12 3 Fabpi–
SV-40 TAgWt bi-transgenic mouse. (A) The a6 integrin subunit is evident at the basal surfaces of epithelial cells distributed from the
base of the crypt (closed arrowhead) through the length of the villus (e.g., closed arrow). (B) Higher power view of a normal villus sec-
tioned at its midpoint, perpendicular to the crypt–villus axis. The arrow points to immunoreactive a6 at the base of enterocytes. (C and
D) The crypt–villus distribution of a6 is similar in transgenic mice and does not differ from the distribution observed in their normal lit-
termate shown in A and B. (E–G) The b4 subunit integrin is present throughout crypt–villus units in normal, Fabpi–SV-40 TAgWt trans-
genic, and bi-transgenic animals. The arrows in G point to a branched (bifurcated) villus. Branching is one manifestation of the dysplasia
observed in the small intestine of bi-transgenic mice. (H–K) Distribution of a5 integrin subunit. H and I show jejunal villi that have been
sectioned at their midpoint, perpendicular to the crypt–villus axis. Immunoreactive protein is present at the base of villus enterocytes
and in cellular components of the lamina propria. J and K show sections cut parallel to the crypt–villus axis. The insets in each of these
two panels show cross sections taken at the midpoint of Fabpi–SV-40 TAgWt and bi-transgenic jejunal villi. The integrin subunit is dis-
tributed from the base to the villus tip in all animals (J and K plus data not shown). (L–O) The b1 subunit follows the distribution of its
a5 partner. L and M show normal jejunal villi sectioned parallel and perpendicular to the crypt–villus axis, respectively. N illustrates re-
sults obtained from cross sections of Fabpi–K-rasVal12 villi. O contains a branched villus (arrows) from a bi-transgenic animal. (P and Q)
Fibronectin shows a similar distribution along the crypt–villus axis of normal and bi-transgenic mice, as that of its receptor, a5b1 integrin.
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or in combination, has no detectable effect on the accumu-
lation of fibronectin (Fig. 6, P and Q) or on the crypt–vil-
lus distribution of two other integrin ligands present in the
ECM: type IV collagen and laminin (data not shown).
Interactions between epithelial cells can also affect their
susceptibility to anoikis and survival (Frisch and Francis,
1994). E-cadherin is the principal epithelial cadherin in the
adult mouse small intestine and is present at the adherens
junctions and basolateral surfaces of all villus enterocytes.
Forced expression of a dominant negative N-cadherin mu-
tant in jejunal villus enterocytes results in a loss of E-cad-
herin from the cell surface, a marked reduction in cellular
pools of E-cadherin, disruption of cell–cell as well as cell–
substratum contacts, and precocious entry into a death
program (Hermiston and Gordon, 1995). In light of this
previous finding, immunohistochemical surveys were con-
ducted with a well-characterized mouse E-cadherin mono-
clonal antibody (Hermiston and Gordon, 1995). The re-
sults indicated that expression of K-rasVal12 and/or SV-40
TAgWt has no appreciable effects on the intracellular or
crypt–villus distributions of E-cadherin (n 5 2–5 mice/geno-
type; data not shown).
Discussion
We have used transgenic mice containing various combi-
nations of K-rasVal12 plus wild-type or mutant SV-40 TAgs
to show that K-rasVal12 augments the apoptosis that accom-
panies a pRB-related reentry of differentiated small intes-
tinal enterocytes into the cell cycle.
The augmented apoptosis occurs through an as yet un-
known mechanism. It does not require p53. It is not ac-
companied by detectable changes in accumulation of regu-
lators of the G1/S transition (pRB, cyclins D1 and E, cdks
2 and 4) or enhanced proliferation. It is not associated with
changes in the crypt–villus patterns of expression of sev-
eral regulators of apoptosis (Bcl-2, Bcl-xL, Bak, Bax, and
c-Raf-1). The enhancement is not accompanied by changes
in the crypt–villus distribution of mediators of epithelial
cell–matrix and cell–cell interactions and survival (e.g.,
a5b1 integrin and its ligand fibronectin or E-cadherin). In
some cases our assays may be too insensitive to rule out in-
volvement. For example, an inability to detect alterations
in the crypt–villus pattern of accumulation of five integrin
subunits (a3, a5, a6, b1, and b4) or E-cadherin does not de-
finitively prove that attachment of enterocytes to the
ECM or to adjacent cells is unperturbed in bi-transgenic
animals, or that integrin-activated intracellular signaling
events that affect survival (e.g., Frisch et al., 1996; Wary et
al., 1996) are fully functional. A recent study using CHO
cells indicated that H-ras and its effector kinase, Raf-1,
function to negatively regulate the ligand binding affinity
of certain integrins (Hughes et al., 1997). Such a finding is
consistent with the notion that an anoikis-like mechanism
may contribute to the increased apoptosis seen in bi-trans-
genic mice.
Because K-rasVal12 is the most commonly mutated onco-
gene in colorectal cancer, our in vivo results have implica-
tions concerning the multistep journey to intestinal neo-
plasia. As in primary cultures of human and rodent cells,
villus enterocytes are not transformed through forced ex-
pression of K-rasVal12. The known collaboration that oc-
curs in primary cell cultures between activated forms of
Ras and pRB-disabling viral oncoproteins such as E1A,
E7, or SV-40 TAgWt also applies to enterocytes. Bi-trans-
genic K-rasVal12 3 SV-40 TAgWt mice exhibit dysplasia in
their villus epithelium by the time that crypt–villus mor-
phogenesis is completed between P21–28. This dysplasia is
manifested in part by branched villi. Branching involves
the epithelium, its underlying ECM, and the lamina pro-
pria (e.g., Fig. 6, G, O, and Q), providing an interesting
model system for examining how the small intestinal epi-
thelium is able to define overall villus structure.
Despite the early onset of this dysplasia, bi-transgenic
animals do not develop small intestinal neoplasms between 2
and 18 mo of age (n 5 40 animals). The lack of progression
may be due to the increased apoptosis produced by K-rasVal12
in this “initiated” cell population with a proliferative ab-
normality. Another contributing factor may be the short
residence time of migrating enterocytes on the villus; with-
out functional anchorage, they are not able to undergo
clonal expansion. As noted in the introduction, K-rasVal12
is the most commonly mutated oncogene in human col-
orectal tumors (Fearon and Vogelstein, 1990). Activating
K-ras mutations are not acquired at the beginning but
rather at intermediate points in the multistep journey to
intestinal neoplasia (Bos et al., 1987; Forrester et al., 1987;
Fearon and Vogelstein, 1990). Our results are consistent
with this observation. K-rasVal12 alone has no detectable ef-
fect on noncycling enterocytes. When expressed in “initi-
ated” enterocytes with a proliferative abnormality, K-rasVal12
can facilitate progression to a dysplastic phenotype. How-
ever, by diminishing cell survival on the villus, the onco-
protein may also impede further progression.
Intestinal neoplasia is thought to be initiated in the
crypt, perhaps at the level of the functionally anchored
stem cell or one of its immediate daughters (Moser et al.,
1992). Although the effect of K-rasVal12 on initiated crypt
epithelial cells is unknown, our studies suggest that on the
villus, K-rasVal12 may serve an editing function for the host,
helping to remove these cells. Additional mutations may be
needed to suppress the proapoptotic response to K-rasVal12.
Such mutations may affect genes encoding one or more
determinants of cell survival. Since downregulation of ap-
optosis can contribute to the late stages of tumor progres-
sion, at least in model systems (Naik et al., 1996), it is
tempting to speculate about the significance of the in-
creased expression of antiapoptotic mediators, such as
Bcl-xL or Bcl-2, that has been noted during progression of
human colorectal tumors (Hague et al., 1994; Bedi et al.,
1995; Bronner et al., 1995; Krajewska et al., 1996). Cross-
ing bi-transgenic K-rasVal12 3 SV-40 TAgWt mice to mice
that overexpress these or other mediators of cell survival
in their gut epithelium provides one way of identifying
molecules that may overcome the K-rasVal12-augmented
apoptosis and thus promote development of gut neoplasia.
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